Changgu Yuehan of Kuanliang International Strategy said that geopolitical risks have been discussed recently, and interest rate increases have also had an impact on the capital market, making investors tend to be conservative; but fortunately, the biomedical industry is one of the defensive investments and is less risky. Vulnerable to economic booms.
Using AI to acquire and retain customers is so easy! Infobip helps brand customers reduce revenue costs and implement precise marketing
Taking Taiwan's biomedical capital market as an example, "Benefiting from the recent acceleration of new drug certification into commercial sales, the overall revenue growth rate is expected to grow from 15% in 2022 to 18% in 2024."
Trend 3: “M&A deal activity” will rebound this year
According to the " 2023 Taiwan Biomedical M&A White iran telegram Paper " released by Zicheng , compared with the situation in 2021, global biomedical industry M&A activities will decline in 2022, but the amount of M&A transactions will increase in Q4 of 2022, which means that "large-scale M&A The number of transaction cases has increased."
Global Biomedical Investment
Statistics on mergers and acquisitions in the global biomedical industry from 2018 to 2022.
Picture/2023 Taiwan Biomedical M&A White Paper
Top ten mergers and acquisitions in the world.png
The top 10 M&A transactions in the global biomedical industry in 2022.
Picture/2023 Taiwan Biomedical M&A White Paper
Zicheng is optimistic that M&A transactions in the global biomedical industry will return to normal levels in 2023. Christian Moldt, head of global health industry trading at PwC Germany, explains why: “Although overall economic conditions are likely to remain challenging in 2023, due to corrections in market prices, coupled with the innovation of biomedical industry companies in order to achieve growth targets and continue to stay ahead of competitors, Business development and transformation remain important motivations for M&A transactions in the global biomedical industry.
